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Characteristics of Fibromyalgia Independently Predict Poorer
Long-Term Analgesic Outcomes Following Total Knee and
Hip Arthroplasty
Chad M. Brummett,1 Andrew G. Urquhart,1 Afton L. Hassett,1 Alex Tsodikov,2
Brian R. Hallstrom,1 Nathan I. Wood,1 David A. Williams,1 and Daniel J. Clauw1
Objective. While psychosocial factors have been
associated with poorer outcomes after knee and hip
arthroplasty, we hypothesized that augmented pain
perception, as occurs in conditions such as fibromyalgia,
may account for decreased responsiveness to primary
knee and hip arthroplasty.
Methods. A prospective, observational cohort
study was conducted. Preoperative phenotyping was
conducted using validated questionnaires to assess pain,
function, depression, anxiety, and catastrophizing. Par-
ticipants also completed the 2011 fibromyalgia survey
questionnaire, which addresses the widespread body
pain and comorbid symptoms associated with character-
istics of fibromyalgia.
Results. Of the 665 participants, 464 were
retained 6 months after surgery. Since individuals who
met criteria for being classified as having fibromyalgia
were expected to respond less favorably, all primary
analyses excluded these individuals (6% of the cohort).
In the multivariate linear regression model predicting
change in knee/hip pain (primary outcome), a higher
fibromyalgia survey score was independently predictive
of less improvement in pain (estimate 20.25, SE 0.044;
P< 0.00001). Lower baseline joint pain scores and knee
(versus hip) arthroplasty were also predictive of less
improvement (R25 0.58). The same covariates were
predictive in the multivariate logistic regression model
for change in knee/hip pain, with a 17.8% increase in
the odds of failure to meet the threshold of 50%
improvement for every 1-point increase in fibromyalgia
survey score (P5 0.00032). The fibromyalgia survey
score was also independently predictive of change in
overall pain and patient global impression of change.
Conclusion. Our findings indicate that the
fibromyalgia survey score is a robust predictor of
poorer arthroplasty outcomes, even among individuals
whose score falls well below the threshold for the
categorical diagnosis of fibromyalgia.
The estimated lifetime risk of symptomatic knee
osteoarthritis is ;45% (1). Between 1991 and 2010 the
number of total knee arthroplasties (TKAs) per capita
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among US Medicare beneficiaries nearly doubled, and
there was a 59% increase in revision TKA (2). Based on
temporal trends in aging and obesity, the numbers of
TKA and total hip arthroplasties (THAs) are antici-
pated to increase substantially in the coming years (3,4).
Although TKA and THA have been shown to improve
chronic pain and function (5), studies estimate that
;20% of TKA and 10% of THA patients fail to derive
the desired analgesic benefit (6–9). Cross-sectional stud-
ies of long-term pain outcomes have identified pain in
other locations, as well as negative affect and cognitions
(i.e., depression and catastrophizing, respectively) as
independent risk factors for lack of improvement in
pain following TKA and THA (7,8,10,11).
One possible explanation for the differences in
long-term analgesic outcomes may be mechanistic.
There is a growing appreciation of the importance of
augmented central nervous system pain processing and
other symptoms in many chronic pain states (12,13). A
number of pain disorders without clear peripheral
pathology have been given specific names, such as
fibromyalgia, irritable bowel syndrome, and interstitial
cystitis. The most “systemic” of these conditions, fibro-
myalgia, is characterized by widespread body pain and
comorbid somatic symptoms (i.e., fatigue, poor sleep,
depression, and memory difficulties), all of which are
thought to be of central nervous system origin (12).
Research has demonstrated that these patients have
alterations in central neurotransmitters that, at least in
part, lead to both augmented pain and sensory process-
ing and the comorbid symptoms. Opioids, nonsteroidal
antiinflammatory drugs, surgical procedures, and other
peripherally directed interventions are generally
thought to be less effective for central pain states (12).
Our group recently showed that patients with higher
fibromyalgia survey scores consumed substantially
more opioids in the acute postoperative period after
TKA and THA (14). Most importantly, the fibromyal-
gia survey score is not just a dichotomous label; rather,
it appears relevant as a continuous variable within the
population (15). For example, every 1-point increase in
the fibromyalgia survey score from 0 to 31 was associ-
ated with consuming an adjusted 9 mg more oral mor-
phine equivalents to treat postoperative pain following
THA and TKA (14).
Additional support for the hypothesis of poorer
outcomes in patients who have characteristics of fibro-
myalgia comes from earlier studies. For example,
poorer long-term analgesic outcomes in arthroplasty
patients have been associated with multifocal pain, one
of the hallmarks of fibromyalgia (6–8,10,16). One of
the physiologic correlates for fibromyalgia and other
conditions where pain is thought to have become cen-
tralized is diffuse hyperalgesia (12). Two recent cross-
sectional postoperative studies using quantitative sensory
testing showed that patients with pain after revision
TKA have more widespread body pain and lower pain
thresholds (17,18). To date, no prospective study has
been performed to show that measures of centralized
pain are associated with poorer arthroplasty outcomes,
nor has any previous study compared the predictive
value of these measures versus classic measures of
negative affect (depression and anxiety) or cognitions
(catastrophizing) already known to be associated with
poor outcomes.
Given the current utilization and future projec-
tions for arthroplasty (2–4), the ability to predict
poorer outcomes and triage patients to alternate anal-
gesic therapies that might be more effective (e.g., cen-
trally acting analgesics) has enormous socioeconomic
implications. Thus, the objective of this prospective,
observational cohort study was to assess the associa-
tions between fibromyalgia survey scores and chronic
pain outcomes after primary TKA and THA. We
hypothesized that patients with higher fibromyalgia sur-
vey scores would report less long-term pain reduction
following arthroplasty.
PATIENTS AND METHODS
Study design. University of Michigan Institutional
Review Board approval was obtained. The reporting of this
prospective, observational cohort study conforms to the
Strengthening the Reporting of Observational studies in Epi-
demiology (STROBE) Statement (19). Between July 27, 2010
and May 31, 2013, adult patients ($18 years old) who were
scheduled for primary, unilateral TKA or THA were prospec-
tively recruited prior to surgery. Patients were excluded if
they were undergoing bilateral arthroplasty, were undergoing
revision arthroplasty, did not speak English, were unable to
provide written informed consent, or were incarcerated. All
patients provided written informed consent. Acute postopera-
tive outcomes (anesthesia/acute pain) from a portion of
this cohort were published earlier (14), but the long-term
surgical outcomes explored herein have not been presented
previously.
Phenotyping battery. Patients completed validated
self-report questionnaires prior to surgery, and other relevant
data were obtained from surgical and anesthesia medical
records. Additional details of the preoperative phenotyping
battery have been described previously (14).
Fibromyalgia survey criteria. The fibromyalgia survey
is a validated self-report measure consisting of 2 scales, with
one assessing widespread body pain and the other evaluating
comorbid symptoms (12,15). First, the Widespread Pain Index
(WPI) was calculated using the Michigan Body Map to assess
the 19 specific body areas described in the measure (score
0–19). The second aspect of the criteria was evaluated using
the comorbid Symptom Severity (SS) scale (score 0–12). The
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resulting total fibromyalgia survey score ranged from 0 to 31.
Previously described cut points were used to categorize
patients as “fibromyalgia positive” (15). Specifically, patients
were classified as fibromyalgia positive if they had a WPI of
$ 7 and SS score of $ 5 or a WPI of 3–6 and SS score of
$ 9 (20).
Knee and hip measures. The Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) was
used for knee/hip-specific pain severity (5 questions, score
0–20), stiffness (2 questions, score 0–8), and functional status
(17 questions, score 0–68) (21).
Pain severity. The 4 pain severity questions from the
Brief Pain Inventory (BPI) (worst, least, average, and right
now; with a numeric rating scale of 0–10, where 05no pain
and 105pain as bad as you can imagine) were used to create
a single composite score (0–10) for severity of overall body
pain (22).
Pain descriptors. The PainDETECT Questionnaire is
a 9-item screening tool used to detect descriptors of neuro-
pathic pain. Scores of $19 suggest that a neuropathic compo-
nent is likely (23). The neuropathic pain assessment was
specific to the surgical site (knee or hip) (23).
Psychological measures. The Hospital Anxiety and
Depression Scale (HADS) contains 7 questions about anxiety
and 7 questions about depression, with a score range of 0 to
3 for each question (score 0–21 for each measure, with higher
scores indicating more depressive symptoms and anxiety)
(24). The Coping Strategies Questionnaire-Catastrophizing
contains a subscale for pain catastrophizing, which is a valid
and reliable measure of this cognition. Scores range from 0 to
36, with higher scores indicating more catastrophizing (25).
In addition, research assistants recorded all opioid
use as an average daily dose. Each opioid was then converted
to oral morphine equivalents using previously described
conversions (26) (Palliative Care Consortium [http://www.gha.
net.au/Uploadlibrary/406205172GRPCC-CPG002_1.0_2011-
Opioid.pdf] and The Hopkins Opioid Program [www.hopweb.
org]). Body mass index (BMI) and the American Society of
Anesthesiologists (ASA) physical function score (an ordinal
measure of comorbidities with a range of 1 to 5 [https://www.
asahq.org/resources/clinical-information/asa-physical-status-
classification-system]) were queried from the anesthesia elec-
tronic medical record (Centricity; General Electric Healthcare).
The primary anesthetic was categorized as general anesthesia
alone, general anesthesia plus femoral nerve block, general
anesthesia plus neuraxial anesthesia (spinal or epidural), or
neuraxial anesthesia alone. In a review of patient records, it
was noted that only 4.2% of the cohort had radiographic evi-
dence of arthritis rated as something other than “severe”
(0.52% mild and 3.65% moderate). Due to the low variability,
radiographic evidence of arthritis was not included as a covari-
ate in the outcomes analyses.
Longitudinal assessment. Patients were evaluated 6
months after arthroplasty using the same questionnaires that
were assessed in the baseline phenotyping noted above. The
outcomes assessments were sent and returned by postal mail.
Postoperative record review. The medical records of
all included participants were reviewed for potential compli-
cations or nonphenotypic factors that might explain more
pain or disability in the 6-month followup period (reviews
conducted by AGU, BRH, and NIW). Patients who had addi-
tional arthroplasty (i.e., THA or TKA for a different joint),
hardware fracture, revision surgery, postoperative joint infec-
tion requiring incision and drainage surgery, and/or other sig-
nificant surgery or postoperative outcomes (e.g., coronary
artery bypass, subdural hematoma) prior to their 6-month
outcomes assessment were excluded from the long-term anal-
yses. These exclusions are displayed in the patient flow dia-
gram (Figure 1) and further detailed in the Results section
below.
Primary and secondary outcomes. Primary outcomes
analyses were conducted excluding the patients who met the
criteria for being “positive” for fibromyalgia to ensure that
the results were not driven by this small subset of patients.
All analytic models were also conducted with the entire
cohort (including fibromyalgia-positive patients) minus the
exclusions previously noted (data not shown). Patients who
had fibromyalgia symptoms but did not satisfy the previously
defined thresholds are referred to as having “subclinical”
disease.
The 6-month change in knee/hip pain (WOMAC pain
subscale) was used for the primary outcome. Secondary out-
comes included change in the composite measure of the BPI
(mean of the current, worst, least, and average pain response
[range 0–10]) and the patient’s global assessment of change.
Statistical analysis. Data were entered into the
APOLO Electronic Data Capture system (27). Missing data
for the validated instruments were handled as follows. Cata-
strophizing, fibromyalgia survey score, and WOMAC scales
were computed with complete data only. BPI scales were cal-
culated as the mean of all items or the mean of 3 items if 1
item was missing. If more than 1 item was missing, no scale
score was computed. The PainDETECT Questionnaire score
Figure 1. Flow diagram showing the recruitment and retention of
the patients.
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was calculated as the sum of all 9 items or the sum of 8 items
if 1 item was missing. If more than 1 item was missing, the
PainDETECT Questionnaire score was not calculated.
HADS subscales were calculated using the sum of all subscale
items. If 1 item was missing, the missing value was imputed
with the mean of the remaining items. The scale score was
then computed as the sum of all items. If more than 1 item
was missing, no scale scores were computed. Data were ana-
lyzed using R software version 3.1.1.
The cohort was divided into thirds based on the pre-
operative fibromyalgia survey score for preoperative descrip-
tive data. These tertiles were not based on previously defined
cut points. The continuous score from the fibromyalgia survey
criteria was used for linear and logistic regression outcomes
models, with the models presented excluding fibromyalgia-
positive patients. Additional models included these patients
for comparison (data not shown). The change in knee/hip
pain (WOMAC pain subscale) and overall body pain (BPI)
were analyzed as a continuous score using multivariate linear
regression models. Both knee/hip and overall pain were also
analyzed using a multivariate logistic regression model with a
successful outcome defined as a 50% improvement in pain 6
months after arthroplasty. The patient’s global assessment of
change was dichotomized as patient responses of “very much
improved” or “much improved” versus all other responses for
a multivariate logistic regression model. Given the invasive
nature of arthroplasty, the “slightly improved” response on
the patient’s global assessment of change was not deemed a
successful outcome. All of the baseline covariates were
included in the regression models. Age, BMI, and self-report
measures were analyzed as continuous variables, and other
demographic responses, primary anesthetic type, ASA score,
and knee versus hip surgery were either dichotomized or
treated as categorical variables as appropriate.
Model-based hypotheses testing and backwards vari-
able selection were conducted using likelihood ratio tests.
Briefly, we identify a set of all potential explanatory variables
as the first step. The second step in building a regression
model is to identify the best combination of explanatory vari-
ables to include in the model. The model is first calculated
with all potential explanatory variables (full model), then
recalculated after dropping the variable with the least signifi-
cant association with the response variable. Significance is
assessed by the likelihood ratio test. The process continues
until all variables remaining in the model are statistically sig-
nificant (28,29). For transparency, the fibromyalgia survey
score results in the full model prior to backwards selection
are presented in the results.
RESULTS
Recruitment and retention. A total of 1,034
patients were approached for participation, of whom
665 agreed to participate (64.3%). The mean6 SD age
of the cohort was 62.36 11.3 years, and 52.3% were
women. The cohort was predominantly white (91.4%),
and 41.6% had TKA (versus THA). There were no dif-
ferences in age (P5 0.76) or sex (P5 0.34) when com-
paring participants to nonparticipants; however, there
was a significantly higher proportion of nonwhites in
the nonparticipant group when compared to partici-
pants (86.3% of the nonparticipants were white and
93.2% of the participants were white; P5 0.001). Some
patients were excluded from the analysis, due to addi-
tional arthroplasty during the followup period (n5 50),
hardware fracture (n5 27), joint infection (n5 25),
revision of the same joint during the followup period
(n5 6), and other medical adverse events recorded
during the followup period (n5 7). Some patients were
excluded for multiple reasons. After postsurgical exclu-
sions withdrawals, and loss to followup, there were 464
patients with 6-month outcome data (80.6% of eligible
participants retained) (Figure 1). Patients lost to fol-
lowup reported a significantly worse preoperative phe-
notype (e.g., greater pain, more anxiety and depressive
symptoms, lower function, etc.).
Higher fibromyalgia survey scores predictive of
poorer outcomes regardless of whether individuals
met criteria for fibromyalgia. There was a wide distri-
bution of fibromyalgia survey scores (mean6 SD
6.356 4.18, median 6, range 29, interquartile range 6).
A total of 6.2% of the patients scored at or above the
previously defined cut points for meeting the criteria
for being “fibromyalgia positive” (15). These patients
were excluded from the outcomes analyses unless oth-
erwise noted. Higher fibromyalgia scores were associ-
ated with higher preoperative pain severity and use of
neuropathic pain descriptors, more negative affect (i.e.,
depression, anxiety), increased tendency to catastroph-
ize pain, worse physical function, and more opioid use
(Table 1).
All of the covariates listed in Table 1 were
included in the multivariate regression models. Seventy-
three patients (18.2%) did not meet the threshold of at
least 50% improvement in the WOMAC pain subscale
for the logistic regression model. The outcome was best
predicted by the fibromyalgia survey score (P 5
0.00032), as well as the baseline WOMAC pain score
and THA (versus TKA) (Figure 2). The fibromyalgia
survey score was predictive of failing to meet the thresh-
old for improvement, with the odds increasing by 17.8%
for every 1-point increase on the scale. The same cova-
riates were predictive in the multivariate linear regres-
sion model for the WOMAC pain subscale (continuous
measure) (Table 2).
The fibromyalgia survey score was also predic-
tive of robust change in all of the secondary outcomes.
The fibromyalgia survey score independently predicted
reduced improvement in overall pain (BPI). For every
1-point increase in the fibromyalgia survey score, pa-
tients reported an adjusted 0.19 points less improvement
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on the 11-point pain scale (Table 3). A total of 157
patients (37.7%) failed to derive 50% improvement in
overall body pain. As with the multivariate linear
regression model, the fibromyalgia survey score was
predictive, with the odds of failing to meet the thresh-
old increased by 30% for every 1-point increase on the
scale (logistic regression odds ratio [OR] 1.30 [95%
confidence interval (95% CI) 1.19–1.42], P, 0.00001).
In addition to the other independent predictors in the
multivariate linear regression model of change in over-
all pain (Table 3), the ASA physical function score and
depression were predictive in the multivariate logistic
regression model.
Thirty-seven patients (8.4%) did not meet the
patient’s global assessment of change threshold for suc-
cess, and the fibromyalgia survey score was again pre-
dictive of failed outcomes. The odds of failing to meet
the threshold for success for the patient’s global assess-
ment of change increased by ;18% for every 1-point
increase in fibromyalgia survey score (OR 1.18 [95%
CI 1.05–1.31], P5 0.0038). The higher tertiles of the
fibromyalgia survey score had higher rates of failure to
meet the thresholds for change in knee/hip pain
(WOMAC knee/hip pain severity [difference not signif-
icant]), overall body pain (BPI), and patient’s global
assessment of change (Table 4).
The models were also conducted with the
fibromyalgia-positive patients included, and fibromyal-
gia survey scores remained predictive of change in lin-
ear and logistic regression models for knee/hip pain
and overall body pain, as well as the patient’s global
assessment of change logistic model (data not shown).
No measure of negative affect (depression, anxi-
ety), negative cognitions (catastrophizing), or neuro-
pathic pain consistently remained in the best models
presented, suggesting that these covariates have less pre-
dictive power than the fibromyalgia survey score. In the
full multivariate models with all of the candidate predic-
tors (prior to backwards selection), the fibromyalgia sur-
vey score was a significant predictor for failure to meet
the threshold for knee or hip pain improvement on the
Table 2. Multivariate linear regression best model for change in
knee/hip pain (WOMAC)*
Variable Estimate SE P
(Intercept) 21.46 0.46 0.0015
Fibromyalgia survey score 20.25 0.044 ,0.00001
Baseline WOMAC pain 0.92 0.042 ,0.00001
THA (vs. TKA) 1.96 0.27 ,0.00001
* Independent predictors of change in pain using the Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
pain subscale (dependent measure) over the 6-month followup
period are shown. Negative numbers indicate less improvement in
pain. Patients categorized as fibromyalgia positive were excluded
from the analysis. R25 0.58. THA5 total hip arthroplasty; TKA5
total knee arthroplasty.
Table 3. Multivariate linear regression best model for change in
overall pain (BPI)*
Variable Estimate SE P
(Intercept) 20.26 0.25 0.30
Fibromyalgia survey score 20.19 0.029 ,0.00001
Preoperative opioids (OME) 20.015 0.0047 0.0016
Other race† 21.49 0.58 0.011
Baseline overall pain 0.80 0.049 ,0.00001
THA (vs. TKA) 0.96 0.18 ,0.00001
* Independent predictors of change in pain using the Brief Pain
Inventory (BPI) over the 6-month followup period are shown. Nega-
tive numbers indicate less improvement in pain. Patients categorized
as fibromyalgia positive were excluded from the analysis. R25 0.44.
OME5 24-hour total oral morphine equivalents (measured in mg);
THA5 total hip arthroplasty; TKA5 total knee arthroplasty.
† Nonwhite, non–African American race.
Figure 2. Predictors of failure to meet the threshold for knee or hip
pain improvement (Western Ontario and McMaster Universities
Osteoarthritis Index [WOMAC] pain subscale). In this multivariate
logistic regression model, patients describing less than 50% improve-
ment in pain on the WOMAC pain subscale 6 months after total
knee arthroplasty (TKA) or total hip arthroplasty (THA) were con-
sidered to have failed to have met the threshold. The fibromyalgia
survey score was predictive, with the odds of failing to meet the
threshold increased by 17.8% for every 1-point increase on the scale.
Higher preoperative WOMAC pain score and THA (versus TKA)
were predictive of improved outcomes. Values are the odds ratio
(OR) 6 95% confidence interval (95% CI). Area under the curve
0.74. Values .1 indicate higher odds of failure.
POORER TKA AND THA OUTCOMES IN PATIENTS WITH FM CHARACTERISTICS 1391
WOMAC in the linear multivariate models (estimate
20.20, P5 0.00014) and logistic multivariate models
(OR 1.17, P5 0.0058), as well as on the BPI in the lin-
ear models (estimate 20.20, P, 0.00001) and logistic
models (OR 1.37, P, 0.00001).
DISCUSSION
In this large, prospective, observational cohort
study of arthroplasty outcomes, patients with higher
preoperative fibromyalgia survey scores were less likely
to report improvement in pain in the affected knee or
hip (Table 2 and Figure 2), overall body pain (Table
3), and global impression of change. To our knowledge,
this is the first study to describe the fibromyalgia survey
criteria (15) as a predictor of long-term pain outcomes
after surgery. Most importantly, this measure showed
this predictive ability across the entire cohort, not just
in the 6% of the individuals studied who met the cate-
gorical criteria for fibromyalgia. This single, simple-to-
administer measure was a powerful predictor of a poor
outcome and was the only preoperative phenotypic
measure to consistently show predictive utility across
the different outcome domains. As such, the measure
may have value in screening for appropriateness for
arthroplasty in the clinical setting.
Patients with higher fibromyalgia survey scores
had higher levels of pain in the affected knee or hip, as
determined by WOMAC scores, and higher levels of
overall body pain, as determined by BPI, preoperatively
(Table 1). As is often noted in trials of analgesic thera-
pies (16), patients with higher baseline pain have more
room to improve and are thus more likely to improve
when change in pain is assessed as the primary out-
come (Table 2 and Figure 2). Nonetheless, despite
starting with higher baseline pain, patients with higher
fibromyalgia survey scores were still less likely to meet
the threshold for change in overall pain and change in
affected knee or hip pain.
The findings of this study provide some addi-
tional mechanistic rationale for a portion of the failures
following TKA and THA. Total joint replacement
addresses what has long been thought to be an exclu-
sively or predominantly peripheral disease. The current
conceptualization of fibromyalgia is that the central
sensitivity inherent to this and related conditions leads
to pain augmentation/amplification (12). Despite the
overwhelming data supporting this conceptualization,
there are some that contest these ideas. Patients with
fibromyalgia survey scores that were elevated but still
subclinical (e.g., not meeting previously described cut
points to be fibromyalgia positive) demonstrated
poorer outcomes. We suggest that augmented central
nervous system pain processing is likely more promi-
nent in patients with moderate and higher fibromyalgia
survey scores when compared to those with lower
scores; however, future studies are needed to assess
this concept. Individuals in this study all had severe
enough radiographic evidence of arthritis to qualify for
arthroplasty, so they did all presumably have some
ongoing peripheral nociceptive input that might benefit
from arthroplasty. However, these data suggest that in
Table 4. Failure rates in the FM tertiles*
All patients
Patients with
low FM
survey score
Patients with
moderate FM
survey score
Patients with
high FM
survey score
P
Overall
group
Low vs.
moderate
Low
vs. high
Moderate
vs. high
Failed to achieve
50% improvement
in knee/hip pain
(WOMAC)
19.87
(16.3–23.45)
16.76
(11.29–22.23)
19.77
(13.91–25.64)
25.42
(17.57–33.28)
0.2 0.46 0.071 0.25
Failed to achieve
50% improvement
in overall pain
(BPI)
40.89
(36.56–45.23)
26.97
(20.45–33.49)
43.24
(36.1–50.38)
60.68
(51.83–69.53)
,0.00001 0.0011 ,0.00001 0.0031
Failed to achieve
change of “much
improved” or
“very much
improved”
(patient’s global
assessment)
9.79
(7.237–12.34)
6.77
(3.217–10.32)
9.14
(4.998–13.28)
17.21
(10.51–23.91)
0.014 0.39 0.0042 0.037
* Values are the percentage (95% confidence interval) of all patients and patients in each tertile of preoperative fibromyalgia (FM) survey
score. Both patients who underwent total hip arthroplasty and those who underwent total knee arthroplasty are included. WOMAC5Western
Ontario and McMaster Universities Osteoarthritis Index; BPI5Brief Pain Inventory.
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some individuals with arthritis or other peripheral noci-
ceptive input, this superimposed pain amplification is
clinically relevant and might even be playing a more
prominent role in a given individual’s overall pain
experience as opposed to what is occurring solely in
the knee or hip (12,13).
The notion that there is a subset of individuals
with osteoarthritis, or any other chronic pain condition,
that has centralized pain augmentation is well sup-
ported by quantitative sensory testing and neuroimag-
ing studies (30,31). This study, however, is the first
large prospective study to show that it may be very
important to use simple screening tools such as the
2011 fibromyalgia survey criteria to identify clinical or
subclinical fibromyalgia in medical practice (17,18,31).
Combined with our recent study showing that this
same measure was also predictive of markedly in-
creased opioid requirements in the immediate post-
operative period (14), it now appears that individuals
with this phenotype respond differentially to treatments
for both acute (i.e., opioids) and chronic (i.e., surgery)
pain. Additional research is needed to identify the pre-
cise biologic underpinnings of the poorer outcomes
associated with higher fibromyalgia survey scores, as
well as whether this measure might finally allow us to
move toward the elusive “personalized analgesia”
sought for acute and chronic pain. It is possible that
patients with higher fibromyalgia survey scores would
be more likely to benefit from therapies targeting cen-
tralized pain, including medications (e.g., serotonin and
norepinephrine reuptake inhibitors, gabapentinoids),
exercise, and cognitive behavioral therapy (12). These
findings could have implications for other pain thera-
pies, including minimally invasive interventions and
surgery for spine pain (32).
Other measures and concepts have been studied
and described as predictive of chronic postsurgical pain
outcomes. Of these, measures of affect, catastrophizing,
and neuropathic pain descriptors have gained a great
deal of interest (7); however, none of these measures
was retained in the best models for the outcomes ana-
lyzed, suggesting that these are at least weaker predic-
tors of the outcomes assessed when compared to the
fibromyalgia survey score. Wylde et al (7) described
depression as independently predicting poorer pain sta-
tus in a cross-sectional study after TKA and THA.
Whereas meeting criteria for depression was predictive,
the adjusted OR for depression (categorical variable)
was only 1.27–1.29. By comparison, they found that the
adjusted OR for having higher pain scores after arthro-
plasty in patients with widespread body pain (pain at
$5 locations) was 11.8 for TKA and 14.8 for THA.
These data are derived from a single, academic
center cohort and therefore may not be generalizable.
In fact, one manner by which we know this cohort to
be unusual is the low overall rate of categorical fibro-
myalgia; only 6% of study participants met the criteria
for fibromyalgia, whereas in other osteoarthritis
cohorts this is generally found to be 10–20% (33).
Also, the cohort was followed up for 6 months after
surgery, and it is possible that some patients may have
continued to improve after that time point. There are
limited data to support continued improvement after 6
months; however, there are multiple postoperative,
cross-sectional studies showing a high proportion of
the population with continued moderate to severe pain
(6–8,10). Hence, we believe that a 6-month time point
allowed for sufficient time to evaluate outcomes and
also avoided additional attrition. In its favor, this study
included the core components recommended by the
Initiative on Methods, Measurement, and Pain Assess-
ment in Clinical Trials (IMMPACT) group (34). The
retention rate was very high; however, the group lost to
followup reported a worse overall pain phenotype,
which could have influenced the results.
The fibromyalgia survey score was a robust pre-
dictor of poorer arthroplasty outcomes. Fibromyalgia-
like features suggest the presence of augmented central
nervous system pain processing and may provide a
mechanistic explanation for the failure of a peripherally
driven intervention in some patients.
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